» Articles » PMID: 35330106

Bone Marrow Mesenchymal Stem Cells and Their Derived Extracellular Vesicles Attenuate Non-Alcoholic Steatohepatitis-Induced Cardiotoxicity Via Modulating Cardiac Mechanisms

Overview
Journal Life (Basel)
Specialty Biology
Date 2022 Mar 25
PMID 35330106
Authors
Affiliations
Soon will be listed here.
Abstract

Cardiovascular-disease (CVD)-related mortality has been fueled by the upsurge of non-alcoholic steatohepatitis (NASH). Mesenchymal stem cells (MSCs) were extensively studied for their reparative power in ameliorating different CVDs via direct and paracrine effects. Several reports pointed to the importance of bone marrow mesenchymal stem cells (BM-MSCs) as a reliable therapeutic approach for several CVDs. Nevertheless, their therapeutic potential has not yet been investigated in the cardiotoxic state that is induced by NASH. Thus, this study sought to investigate the molecular mechanisms associated with cardiotoxicity that accompany NASH. Besides, we aimed to comparatively study the therapeutic effects of bone-marrow mesenchymal-stem-cell-derived extracellular vesicles (BM-MSCs-EV) and BM-MSCs in a cardiotoxic model that is induced by NASH in rats. Rats were fed with high-fat diet (HFD) for 12 weeks. At the seventh week, BM-MSCs-EV were given a dose of 120 µg/kg i.v., twice a week for six weeks (12 doses per 6 weeks). Another group was treated with BM-MSCs at a dose of 1 × 10 cell i.v., per rat once every 2 weeks for 6 weeks (3 doses per 6 weeks). BM-MSCs-EV demonstrated superior cardioprotective effects through decreasing serum cardiotoxic markers, cardiac hypoxic state (HIF-1) and cardiac inflammation (NF-κB p65, TNF-α, IL-6). This was accompanied by increased vascular endothelial growth factor (VEGF) and improved cardiac histopathological alterations. Both BM-MSCs-EV and BM-MSCs restored the mitochondrial antioxidant state through the upregulation of UCP2 and MnSOD genes. Besides, mitochondrial Parkin-dependent and -independent mitophagies were regained through the upregulation of (Parkin, PINK1, ULK1, BNIP3L, FUNDC1) and (LC3B). These effects were mediated through the regulation of pAKT, PI3K, Hypoxia, VEGF and NF-κB signaling pathways by an array of secreted microRNAs (miRNAs). Our findings unravel the potential ameliorative effects of BM-MSCs-EV as a comparable new avenue for BM-MSCs for modulating cardiotoxicity that is induced by NASH.

Citing Articles

Stem cell-derived exosome delivery systems for treating atherosclerosis: The new frontier of stem cell therapy.

Tariq H, Bukhari S, An R, Dong J, Ihsan A, Younis M Mater Today Bio. 2025; 30:101440.

PMID: 39866781 PMC: 11758955. DOI: 10.1016/j.mtbio.2024.101440.


Effect of vitamin B12 on methotrexate-induced cardiotoxicity in rats.

Kuloglu N, Karabulut D, Kaymak E, Akin A, Ceylan T, Yildirim A Iran J Basic Med Sci. 2024; 27(6):733-739.

PMID: 38645491 PMC: 11024404. DOI: 10.22038/IJBMS.2024.74161.16120.


Secretome-based acellular therapy of bone marrow-derived mesenchymal stem cells in degenerative and immunological disorders: A narrative review.

Zohora F, Aliyu M, Saboor-Yaraghi A Heliyon. 2023; 9(7):e18120.

PMID: 37496898 PMC: 10366432. DOI: 10.1016/j.heliyon.2023.e18120.

References
1.
Liu Y, Cox S, Morita T, Kourembanas S . Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5' enhancer. Circ Res. 1995; 77(3):638-43. DOI: 10.1161/01.res.77.3.638. View

2.
Yan X, Lv A, Xing Y, Liu B, Hou J, Huang W . Inhibition of p53-p21 pathway promotes the differentiation of rat bone marrow mesenchymal stem cells into cardiomyocytes. Mol Cell Biochem. 2011; 354(1-2):21-8. DOI: 10.1007/s11010-011-0801-x. View

3.
Fernandez-Gonzalez A, Willis G, Yeung V, Reis M, Liu X, Mitsialis S . Therapeutic Effects of Mesenchymal Stromal Cell-Derived Small Extracellular Vesicles in Oxygen-Induced Multi-Organ Disease: A Developmental Perspective. Front Cell Dev Biol. 2021; 9:647025. PMC: 8007882. DOI: 10.3389/fcell.2021.647025. View

4.
Stavely R, Nurgali K . The emerging antioxidant paradigm of mesenchymal stem cell therapy. Stem Cells Transl Med. 2020; 9(9):985-1006. PMC: 7445024. DOI: 10.1002/sctm.19-0446. View

5.
Kasper P, Martin A, Lang S, Kutting F, Goeser T, Demir M . NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol. 2020; 110(7):921-937. PMC: 8238775. DOI: 10.1007/s00392-020-01709-7. View